Pfizer-BioNTech's COVID-19 Vaccine Becomes First To Receive Full FDA Approval

by Vandana Singh, Benzinga Editor

August 23, 2021 9:58 AM | 1 min read |

The FDA has approved Pfizer Inc PFE and BioNTech SE's BNTX COVID-19 vaccine, making it the first to receive full FDA approval.
The vaccine will now be marketed as 'Comirnaty' to prevent COVID-19 infection in individuals 16 years and older.
The vaccine continues to be available under emergency use authorization (EUA) for individuals 12 through 15 years and a booster shot for certain immunocompromised individuals.
Related: FDA Approves Vaccine Booster Dose Of mRNA COVID-19 Vaccines For Small, Vulnerable Group.
Related content: Benzinga's Full FDA Calendar.
Price Action: PFE shares are up 3.73% at $50.53, and BNTX stock is up +10.20% at $384.07 during the market session on the last check Monday.
Image by x3 from Pixabay

Posted In: Biotech Long Ideas News Health Care FDA Top Stories Movers Trading Ideas General Briefs Coronavirus Covid-19 COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.